Antitrophoblast antibodies are associated with recurrent miscarriages

We investigated patients with unexplained recurrent pregnancy loss for expression of antitrophoblast antibodies using choriocarcinoma cell line JEG-3 because these cells retain many characteristics of normal pregnancy-derived trophoblasts.

Upvote 0 Comment


Nina Rogenhofer, M.D., Robert Ochsenkühn, M.D., Viktoria von Schönfeldt, Ph.D., Rudah Brentano Assef, Christian J. Thaler, M.D., M.I.A.C.

Volume 97, Issue 2 , Pages 361-366.e1



To investigate whether antitrophoblast antibodies are associated with unexplained recurrent miscarriages, we used choriocarcinoma cells JEG-3, since these cells are negative for class I and II antigens, but they do express HLA-G, resembling an antigen expression of endovascular and interstitial trophoblasts.


Case-control study.


Academic research center.


One hundred ninety-four patients with two or more consecutive, idiopathic recurrent miscarriages (RM;


Anti-JEG-3 reactivities were measured by using flow cytometry and comparisons with two in-house standards antibody samples of low and high reactivity.

Main Outcome Measure(s):

Anti-JEG-3 reactivities above the 95% confidence interval of controls were defined as positive.


Sera of RM patients reacted significantly stronger with JEG-3 cells than that of controls. In addition, RM patients significantly more often had positive anti-JEG-3 reactivities (17.5%) than controls 5%. This difference was markedly increased with a subgroup of 80 RM patients who had three or more miscarriages, as 27 of these women (34%) were anti-JEG-3 positive.


Antitrophoblast antibodies show significantly more mean channel shift reactivities, and positive reactivities are significantly more prevalent in RM patients as compared with controls. Such antibodies may be involved in mechanisms affecting pregnancies.

Read the full text at:

Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.